Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
Roswell Park Cancer Institute
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Genmab
Genmab
Genmab
Alliance for Clinical Trials in Oncology
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Incyte Corporation
Children's Oncology Group
Acerta Pharma BV
Canadian Cancer Trials Group
Novartis
Baylor College of Medicine
Fred Hutchinson Cancer Center
Children's Cancer Group, China
Fate Therapeutics
Children's Cancer Group, China
Center for International Blood and Marrow Transplant Research
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
M.D. Anderson Cancer Center
Allogene Therapeutics
Case Comprehensive Cancer Center
M.D. Anderson Cancer Center
Children's Oncology Group
St. Jude Children's Research Hospital
Merck Sharp & Dohme LLC
Dartmouth-Hitchcock Medical Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Hoffmann-La Roche
Dana-Farber Cancer Institute
Celgene
M.D. Anderson Cancer Center
Hoffmann-La Roche
Ohio State University Comprehensive Cancer Center
Regeneron Pharmaceuticals
Center for International Blood and Marrow Transplant Research
Regeneron Pharmaceuticals
Mayo Clinic